Clinical collection
Dermatology & Allergy
Use these references to compare itch-control options, check label constraints, and keep the diagnostic workup in view. The collection connects allergic skin disease differentials with evidence on JAK inhibitors, monoclonal antibodies, ciclosporin, and parasite control.
12 source-cited clinical references
Browse the collection
Canine Lip-Fold Intertrigo: Localization, Sampling and Workup
Separate fold-limited intertrigo from mucocutaneous pyoderma, immune-mediated disease, and oral pathology; use lesion-directed sampling and reassessment.
Read →Canine Ear Margin Dermatosis: Lesion-Directed Diagnostic Workup
Separate adherent follicular casts from pruritic, ulcerative, and ischemic pinnal disease before labeling canine ear-margin lesions an idiopathic cornification disorder.
Read →Canine Footpad Hyperkeratosis: A Lesion-Directed Diagnostic Workup
Separate primary cornification disease from inflammatory, infectious, and metabolic pedal disease using distribution, targeted sampling, histopathology, and selective genetic testing.
Read →Feline Swollen Pinna: Localize Hematoma and Underlying Otitis
A structured approach to feline pinna swelling: distinguish an auricular hematoma from wound or mass, evaluate the ear canal, and plan treatment around the trigger.
Read →Canine Allergic Skin Disease: Diagnostic Workup and Long-Term Planning
A clinician-facing framework for the pruritic dog: minimum dermatologic database, infection and ectoparasite control, diet-trial interpretation, atopy assessment, and longitudinal outcomes.
Read →Ilunocitinib (Zenrelia): A Clinical Guide to the Once-Daily JAK Inhibitor for Canine Atopic Dermatitis
Ilunocitinib (Zenrelia, Elanco) is a once-daily oral JAK inhibitor for canine allergic and atopic dermatitis. This hub covers mechanism, dosing, the head-to-head data versus oclacitinib, the boxed vaccination warning, and where it fits alongside Apoquel, Cytopoint, and ciclosporin.
Read →Sarolaner for Canine Generalized Demodicosis: Efficacy, Class Pharmacology, and Safety
Oral sarolaner-based isoxazolines clear Demodex canis in generalized demodicosis: a masked field study reached 100% mite reduction by Day 90.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evergreen review of pivotal RCTs, 12-month durability, ciclosporin comparison, COLT combination therapy, and the 2024-2025 JAK-inhibitor landscape.
Read →Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
Two controlled studies confirm 98–100% mite-free rates with a single fluralaner administration for canine generalized demodicosis, outperforming imidacloprid/moxidectin — with 2026 data extending single-dose cure to sarcoptic mange and reviews refining the isoxazoline MDR1 neurologic-safety signal.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Evidence-based guide to cyclosporine (Atopica/Cyclavance) for canine atopic dermatitis: RCT efficacy vs placebo and methylprednisolone, the ~4-week onset and prednisolone bridging strategy, long-term safety, vaccination planning, CYP3A4 interactions, and feline PK contrast.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, head-to-head vs prednisolone, ciclosporin, and ilunocitinib, 10-year safety and neoplasia evidence, JAK1 mechanism, combination protocols, and monitoring.
Read →